The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B2 receptor.
The pharmacology of peptide and non-peptide bradykinin B2 receptor ligands was evaluated in the inositol phosphate (IP) production assay in CHO cells expressing the human bradykinin B2 receptor. The effect of single and double alanine mutation of D266 and D284 residues at the human bradykinin B2 receptor was evaluated on the agonist profile of bradykinin (H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH) and the synthetic agonist FR190997 (8-[2,6-dichloro-3-[N-methylcarbamoyl)cinnamidoacetyl]-N-methylamino]benzyloxy]-2-methyl-4-(2-pyridylmethoxy)quinoline). Bradykinin potency (EC50 0.5 nM at the wild-type receptor) was reduced by 16-fold at D266A and D284A mutants and by 2300-fold at the D266A/D284A double mutant. None of the mutants affected the potency or the efficacy of FR190997. Peptide antagonists, Icatibant (H-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Dtic-Oic-Arg-OH) and MEN11270 (H-DArg-Arg-Pro-Hyp-Gly-Thi-c(Dab-DTic-Oic-Arg)c(7gamma-10alpha)) (100 nM) similarly antagonized the concentration-response curve to bradykinin or FR190997 (pA2 values 8.5 and 8.4 versus bradykinin and 8.2 and 8.4 versus FR190997) at the wild-type receptor. Non-peptide antagonists FR173657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-[2,4-dichloro-3-[(2-methyl-8-quinolinyl) oxymethyl]phenyl]-N-methylaminocarbonyl methyl]acrylamide) and LF16-0687 (1-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxy] methyl]-phenyl]sulfonyl]-N-[3-[[4-(aminoiminomethyl)-phenyl]carbonylamino]propyl]-(S)-pyrrolidine carboxamide) (100 nM) showed an equivalent potency values in blocking the IP production induced by bradykinin or FR190997 (pA2 values 8.7 and 8.8 versus bradykinin and 8.8 and 8.6 versus FR190997). Whilst the antagonist potency of FR173657 and LF16-0687 was not affected by D266A/D284A double mutation (IP production induced by the synthetic agonist), that of Icatibant and MEN11270 was reduced by 50- and 200-fold. The antagonist potency of [Ala1]-Icatibant and [Ala2]-Icatibant (pA2 values at wild-type 7.7 and 6.4) was significantly less reduced (20-fold and 13-fold, respectively) by the D266A/D284A double mutation. Our results highlight a crucial role for two aspartic residues, D266 and D284, located at the top of transmembrane segments 6 and 7, in the high-affinity interaction of peptide antagonists with the human bradykinin B2 receptor. An interaction of these receptor residues with the N-terminal basic residues of Icatibant is hypothesized.
Bellucci
Francesca
F
Department of Pharmacology, Menarini Ricerche S.p.A., via Rismondo 12A, 50131, Florence, Italy.
Meini
Stefania
S
Cucchi
Paola
P
Catalani
Claudio
C
Giuliani
Sandro
S
Zappitelli
Sabrina
S
Rotondaro
Luigi
L
Quartara
Laura
L
Giolitti
Alessandro
A
Maggi
Carlo Alberto
CA
D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000378:metabolism*; D065094:Bradykinin B2 Receptor Antagonists; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010446:Peptide Fragments / Q000378:metabolism* / Q000494:pharmacology; D011804:Quinolines / Q000378:metabolism / Q000494:pharmacology; D043782:Receptor, Bradykinin B2 / Q000819:agonists / Q000378:metabolism*
D065094:Bradykinin B2 Receptor Antagonists; C107104:FR 190997; D010446:Peptide Fragments; D011804:Quinolines; D043782:Receptor, Bradykinin B2; D001224:Aspartic Acid; C065679:icatibant; D001920:Bradykinin